The U.S. Food and Drug Administration approved Marlborough, Massachusetts-based Sunovion Pharmaceuticals’ Kynmobi (apomorphine HCl) sublingual film for Parkinson’s disease.

Despite the COVID-19 pandemic, the U.S. Food and Drug Administration has managed to stay fairly on track in terms of evaluating new drug and supplemental new drug applications. Here is a look at what is on the schedule for the next two weeks.

Acorda Therapeutics will terminate approximately 25 percent of headcount as the company initiates a corporate restructuring.

Every year, 60,000 Americans are diagnosed with Parkinson’s disease. It’s a devastating disease that causes degeneration in the part of the brain that helps to control movements. Many people with treatable symptoms can go undiagnosed for years, some even decades. The earlier Parkinson’s is diagnosed, the sooner treatment can begin increasing the potential for better […]

Collaborating researchers at the University of Iowa and Capital Medical University in China found that a drug used to treat enlarged prostate, terazosin, appears able to slow the progress of Parkinson’s disease.

Shares of Acadia Pharmaceuticals were up nearly 70 percent after a Phase III psychosis trial was halted early as the Parkinson’s disease drug Nuplazid hit primary endpoints, positioning the company to seek another potential regulatory approval.

The U.S. FDA approved Kyowa Kirin’s Nourianz (istradefylline) as an add-on treatment to levodopa/carbidopa in adults with Parkinson’s disease who experience “off” episodes.

The U.S. Food and Drug Administration rejected Sunovion Pharmaceuticals’ experimental treatment apomorphine sublingual film (APL-130277) for OFF episodes of Parkinson’s disease.

The U.S. FDA approved Acorda Therapeutics’ Inbrija, the first inhaled formula of levodopa (L-dopa) for the intermittent treatment of OFF episodes in Parkinson’s disease patients.

Acadia Pharmaceuticals Inc. announced that the FDA completed a postmarketing review and issued a clear statement reaffirming the positive benefit-risk profile of Nuplazid (pimavanserin) for patients with Parkinson’s disease psychosis.